Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study

Balkan medical journal - 8 May 2023

Artan Ayşe Serra, Mirioğlu Şafak, İstemihan Zulal, Aksoy Elif, Dirim Ahmet Burak, Çavuş Bilger, Oto Özgür Akın, Çifçibaşı-Örmeci Aslı, Beşışık Fatih, Çalışkan Yaşar, Öztürk Savaş, Yazıcı Halil, Kaymakoğlu Sabahattin, Türkmen Aydın

Abstract excerpt

Background: Treatment using direct-acting antivirals provides high rates of sustained virologic response and a favorable safety profile for patients with chronic hepatitis C virus infection. However, data on the efficacy of direct-acting antivirals in kidney transplant recipients are still limited. Aims: To evaluate the safety and efficacy of fixed-dose sofosbuvir/ledipasvir combination in kidney transplant...

Topics

Join the communities discussing this publication.

Antiviral Agents
Drug Therapy, Combination
Genotype
Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Hepatitis C, Chronic

Kidney Transplantation

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 36960943
DOI: 10.4274/balkanmedj.galenos.2023.2022-10-13
PMCID: PMC10175878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational StudyPMID 36960943Read ↗

Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Semantic proximity Read ↗

HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.Semantic proximity Read ↗

Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Semantic proximity Read ↗

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.Semantic proximity Read ↗

Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience.Semantic proximity Read ↗

Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.Semantic proximity Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.Semantic proximity Read ↗

Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Semantic proximity Read ↗

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.Semantic proximity Read ↗

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.